Q&A: Zymfentra ‘gives patients an option’ for at-home maintenance therapy of IBD

The FDA’s approval of Zymfentra in fall 2023 offers patients the “flexibility” of a subcutaneous therapy option for moderately to severely active ulcerative colitis and Crohn’s disease, Stephen B. Hanauer, MD, told Healio in an interview.
The agency based its decision on data from the randomized, double-blind, phase 3 LIBERTY UC and LIBERTY CD trials, which assessed the efficacy and safety of Zymfentra (Celltrion, infliximab-dyyb) as maintenance therapy following induction of IV infliximab over 54 weeks. In both trials, Zymfentra was superior to placebo in achieving the

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
This website uses cookies and asks your personal data to enhance your browsing experience.